Cantor Fitzgerald Reiterates Overweight Rating for Nyxoah (NASDAQ:NYXH)

Cantor Fitzgerald reissued their overweight rating on shares of Nyxoah (NASDAQ:NYXH) in a research note released on Tuesday,Benzinga reports. Cantor Fitzgerald currently has a $16.00 price objective on the stock.

Several other equities research analysts have also weighed in on NYXH. Oppenheimer reduced their target price on Nyxoah from $15.00 to $13.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. HC Wainwright reduced their price objective on shares of Nyxoah from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Friday, October 11th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $17.00.

Nyxoah Price Performance

Shares of NASDAQ:NYXH opened at $9.49 on Tuesday. The company has a current ratio of 5.47, a quick ratio of 5.16 and a debt-to-equity ratio of 0.09. Nyxoah has a 1 year low of $4.00 and a 1 year high of $20.00. The firm has a fifty day moving average price of $8.97 and a 200 day moving average price of $8.81.

Nyxoah (NASDAQ:NYXH) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.01). The company had revenue of $0.83 million for the quarter, compared to the consensus estimate of $1.93 million. Nyxoah had a negative return on equity of 56.39% and a negative net margin of 1,061.31%. On average, equities analysts expect that Nyxoah will post -1.86 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Nyxoah

Hedge funds have recently modified their holdings of the business. Kovack Advisors Inc. acquired a new position in Nyxoah during the 3rd quarter valued at $96,000. Ikarian Capital LLC bought a new position in shares of Nyxoah during the 1st quarter worth about $684,000. CVI Holdings LLC bought a new position in shares of Nyxoah during the 2nd quarter worth about $1,292,000. Finally, Iron Triangle Partners LP acquired a new position in shares of Nyxoah during the first quarter valued at about $3,413,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.